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Abstract: COPD is a complex disease with multiple pathological components, which we 
unfortunately tend to ignore when spirometry is used as the only method to evaluate the disorder. 
Additional measures are needed to allow a more complete and clinically relevant assessment 
of COPD. The earliest potential risk factors of disease in COPD are variations in the genetic 
background. Genetic variations are present from conception and can determine lifelong changes 
in enzyme activities and protein concentrations. In contrast, measurements in blood, sputum, 
exhaled breath, broncho-alveolar lavage, and lung biopsies may vary substantially over time. 
This review explores potential markers of early disease and prognosis in COPD by examining 
genetic markers in the α1-antitrypsin, cystic ﬁ  brosis transmembrane conductance regulator 
(CFTR), and MBL-2 genes, and by examining the biochemical markers ﬁ  brinogen and C-reactive 
protein (CRP), which correlate with degree of pulmonary inﬂ  ammation during stable conditions 
of COPD. Chronic lung inﬂ  ammation appears to contribute to the pathogenesis of COPD, and 
markers of this process have promising predictive value in COPD. To implement markers for 
COPD in clinical practice, besides those already established for the α1-antitrypsin gene, further 
research and validation studies are needed.
Keywords: chronic obstructive pulmonary disease, biomarker, pathogenesis, prognosis, 
genetics
Introduction
Chronic obstructive pulmonary disease is deﬁ  ned as a disease state characterized by 
airﬂ  ow limitation that is not fully reversible; the airﬂ  ow limitation is usually both 
progressive and associated with an abnormal inﬂ  ammatory response of the lungs to 
noxious particles or gases.1 According to the WHO Global Burden of Disease Study, 
COPD is the ﬁ  fth leading cause of death worldwide.2 Projections from the WHO pre-
dict that COPD will continue to increase in the years to come, challenging the health 
services in countries where cigarette smoking is prevalent. Consequently, we need to 
improve the diagnostic and therapeutical tools against COPD.
COPD is a complex disease with multiple pathological components,3–6 which we 
unfortunately tend to ignore when spirometry is used as the only method to evaluate 
the disorder. Additional measures are needed to allow a more complete and clinically 
relevant assessment of COPD.7–9 This may enable better phenotyping of different 
types of the disease and help improve the evaluation of disease activity and efﬁ  cacy 
of therapy. The earliest potential risk factors of disease in COPD are variations in the 
genetic background. Genetic variations are present from conception and can determine 
lifelong changes in enzyme activities and protein concentrations. In contrast, measure-
ments in blood, sputum, exhaled breath, broncho-alveolar lavage, and lung biopsies 
may vary substantially over time. The best known inherited risk factor for early-onset 
COPD is genetically deﬁ  cient plasma levels of α1-antitrypsin.
In this review we have explored potential markers of early disease and prognosis 
in COPD using data from the prospective epidemiological study, the Copenhagen City 
Heart Study,10–12 and information from two Danish National Registers covering all 
hospital discharges and causes of death in the country. The investigations are focused International Journal of COPD 2009:4 158
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on genetic markers in the α1-antitrypsin and cystic ﬁ  brosis 
transmembrane conductance regulator (CFTR) genes, the two 
most important known genes for obstructive lung disease, 
and the MBL-2 gene in which functional polymorphisms 
have been associated with features of COPD in previous 
reports.13,14 Since COPD is deﬁ  ned by an abnormal inﬂ  am-
matory response to noxious particles or gases, elevated lung 
inﬂ  ammation could also represent an early pathological event 
in COPD. Fibrinogen and C-reactive protein (CRP) correlate 
with degree of pulmonary inﬂ  ammation during stable condi-
tions of COPD,15,6 and could potentially be useful as markers 
of early disease and prognosis in COPD.
α1-antitrypsin deﬁ  ciency and COPD
The Z allele substitutes lysine for glutamic acid at position 
342 in the α1-antitrypsin gene, while the S allele substitutes 
valine for glutamic acid at position 264. The Z allele and 
to a lesser degree the S allele can cause α1-antitrypsin to 
polymerise in hepatocytes leading to reduced plasma lev-
els of α1-antitrypsin and higher risk for COPD.17 Severe 
α1-antitrypsin ZZ deﬁ  ciency is the most important known 
genetic risk factor for COPD. Individuals with less severe 
α1-antitrypsin deﬁ  ciency (MS, MZ, SZ genotypes) could also 
have an increased susceptibility for COPD. We compared 
plasma α1-antitrypsin level, decline in lung function, and risk 
of hospitalization for COPD in α1-antitrypsin MS, MZ, SZ 
genotypes versus. controls.18,19 We found a stepwise reduc-
tion in plasma α1-antitrypsin with increasing severity of the 
α1-antitrypsin genotype (Figure 1). The MZ, SZ and ZZ geno-
types were associated with reduced plasma α1-antitrypsin, 
greater annual FEV1 decline (ZZ only borderline), and with 
greater risks of spirometry-deﬁ  ned airway obstruction and 
COPD (MZ and SZ only borderline for airway obstruction) 
(Figure 1). Although MS was associated with lower plasma 
α1-antitrypsin level, this genotype did not confer greater FEV1 
decline or increased risk of airway obstruction and COPD.
To put these results into an international context, we 
identiﬁ  ed previous studies on COPD risk in intermediate 
α1-antitrypsin deﬁ  ciency, aggregated the results using meta-
analyses, and calculated summary risk estimates for COPD in 
MS, MZ, and SZ individuals20,21 (Figure 2). Seventeen studies 
were included in meta-analyses on MS, 16 in meta-analyses 
on MZ, and 6 in meta-analyses on SZ. The summary odds 
ratio for MS was increased at 1.2 (1.0–1.4), the summary 
odds ratio for MZ was increased at 2.3 (1.6–3.4), and the 
summary odds ratio for SZ was increased at 3.3 (1.2–8.6). 
Previous publications indicate that the magnitude of 
the COPD risk in MZ differs by study design. Thus, we 
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Figure 1 Plasma α1-antitrypsin, FEV1 decline, and risk of airway obstruction or 
COPD by α1-antitrypsin genotype.   Values are mean ± SEM, odds ratio [OR] (95% CI), 
or hazard ratio [HR] (95% CI). ***p   0.001, **p   0.01, *p   0.05. Data derived 
from Dahl M, Tybjaerg-Hansen A, Lange P,   Vestbo J, Nordestgaard BG.  Ann Intern Med. 
2002;136:270–279.18
performed a meta-analysis for MZ stratiﬁ  ed by study design. 
After stratiﬁ  cation, the summary odds ratio for MZ was 
1.5 (0.97–2.3) in cross-sectional studies and 3.0 (2.1–4.3) in 
case-control studies. The summary odds ratios for MS and 
SZ, and the summary odds ratio for MZ in cross-sectional 
studies, did not differ considerably from the results provided 
by the Copenhagen City Heart Study.18–21International Journal of COPD 2009:4 159
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Figure 2 Cross-sectional and case-control studies of COPD risk in protease inhibitor MS, MZ, and SZ heterozygotes versus MM individuals. Box sizes are proportional to 
inverse-variance weights (random effects model). Lines represent 95% conﬁ  dence intervals. Adapted with permission from Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK, 
Nordestgaard BG. Eur Respir J. 2005;26:67–76.20 Copyright © 2005 European Respiratory Society Inc, and from Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silver-
man EK. Thorax. 2004;59:843–849.21 Copyright © BMJ Publishing Group.
Abbreviation: PI, protease inhibitor.
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The meta-analyses suggest that risk of COPD is 
marginally elevated in MS and MZ individuals (in 
cross-sectional studies), whereas the more severe SZ geno-
type is an important risk factor for COPD. It is possible that 
MS, MZ, and SZ have greater risk estimates in subgroups 
of patients or in individuals with other additional risk fac-
tors for COPD, but further studies of very large populations 
are needed to determine if this is the case. We now offer an 
analysis in COPD patients that detects the S and Z alleles of 
the α1-antitrypsin gene with a simultaneous measurement of 
plasma α1-antitrypsin.22 This will help clinicians to detect 
α1-antitrypsin-deﬁ  cient individuals with high risk of COPD, 
and opens up for early smoking prevention counselling and 
potential therapy to individuals identiﬁ  ed with α1-antitrypsin 
deﬁ  ciency through this new analysis.
Cystic ﬁ  brosis F508del and COPD
Cystic ﬁ  brosis is characterized by progressive obstructive lung 
disease in homozygous individuals, and it is possible that het-
erozygotes for cystic ﬁ  brosis are at increased risk of less severe 
forms of obstructive lung disease. To examine this, we screened 
9141 individuals for the common F508del allele, and we com-
pared lung function and prevalences of COPD and asthma in 
F508del heterozygous individuals versus noncarriers.23,24
Two hundred and ﬁ  fty individuals were heterozygous and 
none homozygous for the cystic ﬁ  brosis F508del allele.23,25 
Among heterozygotes, none had previously been admitted 
to a hospital due to cystic ﬁ  brosis or carried an additional 
394delTT or N1303K allele in the CFTR gene.24 Second to 
the F508del allele, the 394delTT and N1303K alleles are 
the two most common cystic ﬁ  brosis alleles in Denmark 
with allele frequencies of about 1% or more in the Danish 
population.26
Based on triplicate measurements of pulmonary function, 
we found that heterozygous individuals had lower FEV1 
and FVC than noncarriers (Figure 3).24 Consistent with this, 
heterozygous individuals also reported that they had asthma 
more often than noncarriers, whereas the prevalence of 
COPD did not differ between the two groups (Figure 4).23,24 
These ﬁ  ndings were independent of inﬂ  uence from the com-
mon but less severe polythymidine tract variants in intron-8 
of the CFTR gene.27 The shorter this polythymidine tract is, 
the more often exon-9 is skipped from CFTR mRNAs lead-
ing to a CFTR protein without chloride activity.28 Studies of 
asthma risk in cystic ﬁ  brosis heterozygotes, however, have 
not convincingly shown increased asthma among heterozy-
gotes.23,24,27,29–39 Combining all the available data from the 
literature in a meta-analysis,23,29,31,34–37,39 the summary odds 
ratio for asthma in cystic ﬁ  brosis/F508del heterozygotes is 
1.3 (1.1–1.6; p = 0.01) (Figure 5).
In conclusion, cystic ﬁ  brosis F508del heterozygotes are 
not at greater risk of COPD, but may be overrepresented 
among people with asthma and have poorer lung func-
tion than non-carriers. Combining recent reports from the 
literature, the risk for asthma in cystic ﬁ  brosis heterozygotes 
is roughly 30% elevated. Thus, F508del cannot be used as 
a biomarker for COPD or asthma in clinical settings. It is 
possible that F508del can be used as a clinical marker for 
asthma in certain subgroups of patients in the future, when 
other susceptibility markers for asthma are available.
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Mannose-binding lectin and COPD
Mannose-binding lectin (MBL) is an acute phase protein 
secreted from the liver.40,41 It has antibody-like function 
in the innate immune system, where it binds sugarmoieties 
on microorganisms and on apoptotic cells. Bound MBL can 
clear its targets through promoting opsonophagocytosis or by 
activating the complement system through MBL-associated 
protease 1 and 2. Deﬁ  ciency of MBL levels/activity in plasma 
due to polymorphisms in the MBL-2 gene is thought to 
weaken normal innate immune functions against microorgan-
isms and apoptotic cells in the body.42 Genetically reduced 
MBL in plasma raises the susceptibility for disease in COPD 
and asthma.13,14,43 Thus, we determined the risk of COPD and 
asthma in MBL deﬁ  cient individuals versus controls in our 
study of the population at large.44 We did not ﬁ  nd an increased 
risk of COPD or asthma with MBL deﬁ  ciency (Figure 6). 
The risk of death due to respiratory disease was unaffected 
by MBL deﬁ  ciency status.
Only few other studies have examined the potential relation 
between MBL deﬁ  ciency and obstructive lung disease.13,14,43 
Our study had ample statistical power to test the hypothesis 
that MBL deﬁ  ciency is associated with risk of obstructive 
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lung disease. In conclusion, genetic MBL deﬁ  ciency is not a 
major risk factor for COPD in the Danish general population. 
At present, genetic variants in the MBL-2 gene cannot be used 
as biomarkers of obstructive lung disease.
In children, MBL could have an important function 
in pulmonary host defence during the vulnerable period 
when the adaptive immune system is immature.45 We tested 
whether adult MBL deﬁ  cient individuals more often than 
controls were hospitalized or died due to pulmonary infec-
tion, but found no increased frequency of pulmonary infec-
tion with MBL deﬁ  ciency.44 These results suggest that MBL 
does not have a major role in pulmonary defence against 
microorganisms in adult Danish individuals.
Other genetic markers of COPD
We have used a candidate gene approach to evaluate 
genetic markers in the α1-antitrypsin, CFTR, and MBL 
genes, and their relation to COPD. Other approaches 
include linkage studies, transcript-expression analyses, 
and animal model genetics, all of which can be used to 
identify certain genetic candidates for COPD. To trans-
late results from such studies into clinical medicine, 
an estimation of risk of disease is needed. This can be 
achieved through association studies of the population at 
large such as ours.
In COPD recent focus has been on the enzyme serine pro-
teinase inhibitor E2 (SERPINE2), as this enzyme is a family 
relative of α1-antitrypsin (SERPINA1), the most important 
risk factor of inherited COPD. Supporting that SERPINE2 
is of importance to COPD susceptibility, polymorphisms 
in the SERPINE2 gene have been shown to associate with 
features of COPD.46,47 The enzymes epoxide hydrolase 1 
(EPHX1) and superoxide dismutase 3 (SOD3) are also of 
potential interest as markers in COPD,48–51 as these enzymes 
may inhibit increased oxidative stress in the lungs due to 
cigarette smoke inhalations. Comprehensive reviews on 
other candidate genes in COPD are readily available.52,53
Plasma ﬁ  brinogen and COPD
Pulmonary inflammation in COPD is associated with 
increased levels of acute phase reactants in plasma, and 
these reactants could potentially be used to predict risk of 
future COPD events. To test whether the acute phase reactant 
ﬁ  brinogen predicts future COPD, we determined lung func-
tion and relative risk of COPD hospitalization in individuals 
with increased levels of plasma ﬁ  brinogen. We found that 
individuals with baseline plasma ﬁ  brinogen of more than 
3.3 g/L versus less than 2.7 g/L had reduced lung function, 
increased cumulative incidence of COPD hospitalization 
(Figure 7), and an increased relative risk of 1.7 (1.1–2.6) for 
COPD hospitalization during 6 years of follow-up.54 These 
ﬁ  ndings suggest that plasma ﬁ  brinogen is a signiﬁ  cant predic-
tor of future COPD in the population at large.
A later study conﬁ  rms plasma ﬁ  brinogen as a marker of 
COPD prognosis: Gan et al estimated a 0.37 g/L difference 
in plasma ﬁ  brinogen between COPD patients and controls.15 
The clinical utility of plasma ﬁ  brinogen as a biomarker of 
COPD seems limited based on its low predictive value for 
COPD.54 IL-6 regulates ﬁ  brinogen production from the liver. 
Thus, the results point to an important function for ﬁ  brino-
gen, IL-6, or factors upstream of IL-6 in the pathogenesis of 
COPD. Further studies are required to elucidate which part, 
if any, ﬁ  brinogen or IL-6 has in the progression of COPD.
Plasma C-reactive protein 
and COPD
COPD is associated with elevated C-reactive protein (CRP) 
concentration in serum which equals concentrations in 
plasma,15 and it is possible that CRP as a marker of pulmo-
nary inﬂ  ammation could be used to predict risk of future 
COPD events. To test whether plasma CRP predicts future 
COPD events, we measured CRP in a subgroup of individu-
als with high risk of clinical COPD, that is, individuals with 
spirometry-deﬁ  ned airway obstruction.55 During 8 years of 
follow-up, we recorded admissions and deaths due to COPD, 
and relative risks for COPD hospitalization or deaths were 
determined. We found that individuals with serum CRP of 
more than 3 mg/L versus  3 mg/L at baseline had increased 
cumulative incidence of COPD hospitalization and death 
(Figure 8), an increased hazard ratio of 1.4 (1.0–2.0) for 
MBL deficiency
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Death form
respiratory disease
0.5
Hazard ratio
12 0.5 1 2
COPD
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Figure 6 Hazard ratios for asthma and COPD by mannose-binding lectin 
deﬁ  ciency.   Adapted with permission from Dahl M, Tybjaerg-Hansen A, Schnohr P, 
Nordestgaard BG. J Exp Med. 2004;199:1391–1399.44 Copyright © 2004 Rockefeller 
University Press.International Journal of COPD 2009:4 163
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COPD hospitalization, and an increased hazard ratio of 
2.2 (1.2–3.9) for COPD death.55 Absolute risks for COPD 
hospitalization and death increased with baseline serum 
CRP levels (Figure 9). The highest absolute 10-year risks for 
COPD hospitalization and death were 54% and 57% among 
individuals with baseline CRP above 3 mg/L, above 70 years 
of age, with a tobacco consumption of more than 15 g/day, 
and an FEV1% predicted less than 50%.
The data suggests an important role for CRP, or its main 
regulatory cytokine IL-6, in COPD progression and develop-
ment. Supporting a role for IL-6 in COPD pathogenesis, IL-6 
may stimulate inﬂ  ammatory cell recruitment to the lung, and 
lead to emphysema-like airspace enlargement and respira-
tory muscle wasting in animal models of lung disease.56–65 
Thus, our own and previous data seem to suggest that IL-6 
or factors upstream of IL-6 are involved in the pathogenesis 
of COPD. In the future, CRP levels could be used clinically 
to assess prognosis in patients with airway obstruction. High 
absolute risk as depicted in Figure 9 may motivate patients at 
the highest risk to quit smoking or to receive medication.
Other biochemical markers 
of COPD
In COPD, biochemical biomarkers represent a new ﬁ  eld that 
we have just begun to explore. The potential is great. COPD 
is a multicomponent disease for which airway inﬂ  ammation 
plays an imperative role. This component, among several 
others, needs descriptive measures to provide a more com-
prehensive and clinically accurate assessment of COPD.
Biochemical COPD markers can be measured in exhaled 
breath, induced sputum, bronchoalveolar lavage ﬂ  uid, lung 
biopsies, and plasma. Compared to biomarkers measured in 
other sample material, biochemical markers determined in 
plasma are reliably measured using equipment that is cost-
effective and readily available in clinical settings. However, 
biochemical markers, and in particular those measured in 
plasma, may be modulated by morbidities other than COPD, 
and thus may in some circumstances represent epiphenomena 
unrelated to the COPD phenotype.
The validation of a biomarker has been proposed to involve 
the following three phases:8 1) demonstration that the marker 
frequency/magnitude is associated with a clinical outcome. 
2) Phase I/II trials demonstrating effects on the marker with 
therapeutic intervention. Are there dose-dependent effects of 
treatment on the marker? 3) Demonstration that treatment-
related changes in the marker are associated with positive 
changes in clinical outcomes. Is the marker applicable to all 
disease stages and all interventions?
In COPD the biochemical markers are many, but these 
have been less well investigated than biochemical markers 
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in asthma. When evaluating therapies for COPD, markers 
that could surrogate for critical pathological processes in 
COPD would be highly warranted. For example desmosine 
as part of mature elastin indicates elevated turnover of elastic 
ﬁ  bres in COPD.66 Novel lung-speciﬁ  c markers also appear 
promising,67,68 in particular surfactant protein-A, which is 
elevated in lung tissue and sputum in COPD patients when 
compared with controls in a proteomics study.69 The explora-
tion and validation of potential markers for COPD is currently 
ongoing and no speciﬁ  c marker has so far been implemented 
for clinical use.7–9,70–72
Conclusions
Using data from up to 9245 adult participants from the 
Copenhagen City Heart Study and information from the 
national Danish Hospital Discharge Registry and the national 
Danish Causes of Death Registry, we explored new potential 
markers of COPD.
The risk of COPD is marginally elevated for the genetic 
biomarkers, MS and MZ, in the α1-antitrypsin gene, 
whereas the SZ biomarker is an important risk factor of 
COPD. The ZZ genotype is already in clinical use as a 
genetic marker for early-onset COPD. We have set-up an 
analysis for diagnosing the SZ and ZZ genotypes together 
with measurement of plasma α1-antitrypsin levels to be 
used broadly, including in COPD patients. This will help 
clinicians to detect α1-antitrypsin-deﬁ  cient individuals 
with a high risk for COPD, and opens up for early smoking 
prevention counseling and potential therapy for individu-
als identiﬁ  ed with α1-antitrypsin deﬁ  ciency through this 
new analysis.
The genetic biomarker, F508del, in the cystic ﬁ  brosis 
gene was not associated with COPD, but with increased 
asthma risk. Aggregating results from previous reports, the 
risk of asthma is only marginally elevated. Thus, F508del 
cannot at present be used as a marker of COPD or asthma 
in clinical settings.
Genetic deﬁ  ciency of MBL is not a major risk factor for 
COPD or asthma, and it appears that genetic variants in the 
MBL-2 gene cannot at present be used as biomarkers for 
obstructive lung disease in the Danish population.
Elevated plasma ﬁ  brinogen and CRP levels were associ-
ated with increased COPD risk and may be good for prog-
nostication once a diagnosis of COPD has been established. 
In the future after further validation, it is possible that these 
markers, particularly CRP, can be used to categorise individ-
uals with low, medium, or high risk of COPD, and thus point 
out patients in need of intensiﬁ  ed prevention and treatment 
for COPD. Furthermore, the observed association between 
COPD and elevated ﬁ  brinogen and CRP levels suggests that 
either factor or upstream factors regulating ﬁ  brinogen and 
CRP expression are important players in the pathogenesis 
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of COPD. To determine whether ﬁ  brinogen or CRP are 
causally related to COPD, we are currently investigating 
if genetically increased levels of ﬁ  brinogen and CRP are 
associated with increased risk of future COPD. We anticipate 
that ﬁ  brinogen and CRP-regulating factors (IL-6, TNF-α, 
IL-1) rather than ﬁ  brinogen and CRP themselves are involved 
in COPD pathogenesis, as IL-6, TNF-α, and IL-1 are already 
factors with established functions in COPD. IL-6 is involved 
in inﬂ  ammation, vascular permeability, and cell proliferation, 
while TNF-α, and IL-1 initiates and maintains inﬂ  ammation, 
and activates endothelial and epithelial cells.6
The best known early disease markers for COPD remain 
genetic variations in alpha-1-antitrypsin. They cause 
lifelong reduced levels of alpha-1-antitrypsin in plasma 
and increase the risk for COPD. As such, future studies 
on markers in COPD should ideally demonstrate associa-
tion between a marker and COPD, as well as change in the 
COPD risk with changes in the marker concentration or 
function (genetically or medically induced). Randomized 
pharmacological trials or mendelian randomization 
designs are useful in this regard and will enable us to 
assess the importance of early markers for COPD much 
better. The study of disease markers in COPD can improve 
the phenotyping of different types of COPD. Linking 
the markers to critical pathologic events in COPD can 
provide novel insights into the pathogenesis of COPD. With 
the recent focus on heterogeneity in COPD and the mounting 
efforts in identifying novel markers for COPD this research 
ﬁ  eld seems in progress.
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